Marquette Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Marquette Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-57,876	Closed	-$144K	–	381
2022 Q2	$144K	Buy	57,876 +36,074	+165%	+$72K	0.04%	96
2022 Q1	$65K	Buy	21,802 +5,183	+31%	+$22.1K	0.02%	175
2021 Q4	$117K	Buy	+16,619	New	+$138K	0.02%	136

Other funds holding TERN

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Marquette Asset Management's TERN Position: Q3 2022 in Review

Marquette Asset Management sold out of Terns Pharmaceuticals (TERN) in Q3 2022, closing a stake of 57,876 shares — an estimated $144K sold.

Marquette Asset Management first reported a position in TERN in Q4 2021 and held it in 3 quarters. The position peaked at $144K in Q2 2022. 45 funds tracked by Wall St. Rank hold TERN as of Q3 2022.

Marquette Asset Management reported no remaining Terns Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Marquette Asset Management sold 57,876 Terns Pharmaceuticals shares in Q3 2022, an estimated $144K.
Marquette Asset Management first reported a position in Terns Pharmaceuticals in Q4 2021 and held it in 3 quarters.
Marquette Asset Management's Terns Pharmaceuticals position peaked at $144K in Q2 2022.
45 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2022.

Based on Marquette Asset Management's 13F filing for Q3 2022, filed 6 Oct 2022.